Showing results (271-280 of 596) with videos related to

Sort By:
Pageof 60
Archives of Neurology|June 1, 1997
Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementiaJ V Bowler, M Eliasziw, R Steenhuis, et al.
American Journal of Surgery|December 13, 2012
Mild hyperglycemia, but not glucagon-like peptide 1 predicts poor outcome after injuryR Stephen Smith, William R Fry, Frances H Philp, et al.
Brain & Development|June 25, 2013
Lower limb muscle volumes in bilateral spastic cerebral palsyJonathan J Noble, Nicola R Fry, Andrew P Lewis, et al.
The Journal of Pharmacy and Pharmacology|March 1, 1993
Structural requirements for the direct and cytochrome P450-dependent reaction of cyclic alpha,beta-unsaturated carbonyl compounds with glutathione: a study with coumarin and related compoundsJ R Fry, J H Fentem, A Salim, et al.
Chemico-Biological Interactions|February 1, 1979
The early effects of chemical carcinogens on adult rat hepatocytes in primary culture: I. Quantitative changes in intracellular enzyme activities following a single dose of carcinogenR K Lowing, J R Fry, C A Jones, et al.
Spine|July 1, 1991
Radiographic and histologic effects of chondroitinase ABC on normal canine lumbar intervertebral discT R Fry, J C Eurell, A L Johnson, et al.
American Journal of Clinical Oncology|February 1, 1995
Carcinoma of the anal canalR J Myerson, S J Shapiro, D Lacey, et al.
The American Surgeon|August 1, 1997
Sonographic examination of abdominal trauma by senior surgical residentsS J Kern, R S Smith, W R Fry, et al.
Brain Injury|October 1, 1989
Employment outcomes of persons following traumatic brain injury: pre-injury, post-injury, and supported employmentP Wehman, J Kreutzer, M West, et al.
Expert Opinion on Pharmacotherapy|August 27, 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97Eva Havrdova, Michael Hutchinson, Nuwan C Kurukulasuriya, et al.
Pageof 60